Supercharged immune cells take on Hard-to-Treat lymphoma
NCT ID NCT01192464
First seen Feb 06, 2026 · Last updated May 20, 2026 · Updated 13 times
Summary
This early-phase study tests a new way to fight Hodgkin and non-Hodgkin lymphoma that has returned or not responded to standard treatment. Researchers take a patient's own immune cells (T cells), add a special receptor that targets the CD30 protein on lymphoma cells, and also train them to recognize the common EBV virus to help them last longer in the body. The main goal is to see if this treatment is safe and to find the best dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN'S LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.